NAD+ is often used as part of a supplement combination rather than as a single ingredient. Popular combinations include NAC, berberine, omega-3 fatty acids and nicotinamide riboside. Some products labelled as „NAD+” also rely mainly on nicotinamide riboside as an ingredient intended to increase NAD+ levels. However, these combinations do not operate via the same biological pathways, and direct research concerning the combinations themselves is limited. In this guide, we discuss each of these popular combinations, how the individual ingredients work, the reasons for combining them with NAD+, and what current research shows and does not confirm regarding their combined use.
NAD+ and NAC (N-acetylcysteine): why are they combined?
NAC, or N-acetylcysteine, is an acetylated form of the amino acid cysteine. It is used primarily as a precursor to glutathione, one of the body's main intracellular antioxidants, and has long had an established clinical use as a standard treatment for paracetamol overdose [1].
NAC differs chemically and functionally from NAD+. It is not a nicotinamide-based compound and does not directly enter the NAD+ biosynthesis pathway.
The rationale for combining both compounds stems from an indirect link within cellular redox biology.
Glutathione exists in reduced and oxidised forms. The regeneration of oxidised glutathione to its active, reduced form depends on NADPH, a phosphorylated compound related to NAD+, which is involved in cellular antioxidant and biosynthetic reactions [2].
This provides a mechanistic rationale whereby NAC supports glutathione availability, whereas NAD+-related metabolism is linked to a broader pyridine nucleotide pool, also encompassing NADPH.
These pathways are therefore linked within a broader cellular redox system, but the relationship is indirect rather than resulting from a direct interaction between NAC and NAD+.
No dedicated human clinical trial specifically testing NAC together with an NAD+ precursor has been identified. As a result, claims regarding the synergy of the two ingredients are based primarily on their separate roles in redox biology, rather than on direct evidence showing that the combination provides a greater effect than each ingredient used alone.
Each of the ingredients has its own evidence base, with NAC having a significantly longer and better-established history of clinical use than NAD+ precursors. However, the specific commercial combination has not been independently evaluated in a published clinical trial.
NAD+ and berberine: combination in patches and supplements
Berberine is a plant-derived compound studied mainly for its effects on glucose and lipid metabolism.
One of her main proposed mechanisms involves the activation of AMPK, or AMP-activated protein kinase, an important cellular enzyme responsible for sensing energy status [3].
AMPK differs from the NAD+/sirtuin pathway, although both systems interact at several points within the broader network regulating cellular energy metabolism.
This provides a biological rationale for combining berberine with NAD+-related compounds, but does not prove that the combination leads to a synergistic clinical effect.
Such a combination appears particularly frequently in transdermal products, including patches advertised as „Berberine x NAD”. Some formulations also contain additional ingredients, such as moringa.
The patch form introduces an additional pharmacological issue, since NAD+ and berberine have clearly different molecular properties.
NAD+ has a molecular mass of approximately 663 daltons and is heavily charged. These properties present a significant barrier to passive penetration through intact skin and mean that NAD+ exceeds the general molecular size range considered favourable for passive percutaneous absorption.
Berberine is smaller and has a molecular mass of about 336–390 daltons, depending on the salt form.
This means that two ingredients contained in the same transdermal product can have very different skin permeation properties. Promoting them as a single „stack” does not prove that both ingredients are absorbed through the skin to the same extent.
No dedicated human clinical trials have been identified that specifically test NAD+ or its precursors together with berberine, either in patches or via other routes of administration.
Claims regarding combined or synergistic action are therefore based on separate biological justification and data for each ingredient, rather than on direct data concerning that combination in humans.
NAD+ and nicotinamide riboside: do they act on the same pathway?
Nicotinamide riboside, or NR, differs from NAC and berberine because it is not an independent compound acting on a separate biological pathway.
NR is a precursor of NAD+ [4].
The organism converts NR via enzymatic pathways that ultimately contribute to the production of NAD+. As a result, combining the product designated as direct „NAD+” with NR is better understood as acting on the same biochemical endpoint from different starting forms, rather than as a combination of two clearly independent mechanisms.
This distinction is particularly important because the way products are labelled can give the impression that NAD+ and NR are two separate, complementary active ingredients.
From a biochemical point of view, both approaches are ultimately aimed at increasing the NAD+ pool.
No specific safety issue resulting solely from the direct combination of NAD+ with NR has been documented. However, dedicated safety and efficacy studies evaluating commercial products containing both forms have not been identified.
Such a combination should not therefore be automatically interpreted as providing two independent mechanisms of action.
This differs from combinations such as NAD+ with NAC or berberine, where the ingredients mainly participate in separate biological pathways, even though they may indirectly connect with each other.
This distinction is also important when comparing evidence supporting different forms related to NAD+.
Oral NR currently has significantly more direct human clinical trial data than direct oral NAD+. The presence of both NR and NAD+ in the same formulation therefore does not in itself prove an additional clinical benefit over what the better-studied precursor can provide.
NAD+ and omega-3: what is the purpose of this combination?
Omega-3 fatty acids, particularly EPA and DHA, have an established evidence base that is largely independent of NAD+ research.
EPA, or eicosapentaenoic acid, and DHA, or docosahexaenoic acid, have been widely studied in the context of cardiovascular biology and inflammatory processes.
Mechanistically, EPA and DHA interact with pathways involving arachidonic acid and enzymes such as COX and LOX, which are involved in the production of signalling molecules associated with inflammation [5].
They can alter the profile of lipid-derived signalling pathways and also serve as precursors of specialised pro-resolving mediators involved in the resolution of inflammation [5].
These mechanisms are largely distinct from the NAD+/sirtuin pathways discussed in NAD+ research.
For this reason, the rationale for combining omega-3 fatty acids with NAD+ precursors is generally broader than the mechanistic arguments used for some other NAD+ combinations.
Commercial formulations can position such a combination in the context of cellular, metabolic, or cardiovascular health, or healthy ageing.
However, this is a combination of two separately researched supplement categories, rather than a well-established biochemical synergy between omega-3 fatty acids and NAD+ precursors.
No dedicated human clinical trials specifically testing an NAD+ precursor together with omega-3 fatty acids as a single intervention have been identified.
The evidence therefore comes from separate research databases concerning omega-3 fatty acids and NAD+ precursors, rather than from studies showing that combining them provides greater effects.
General issues concerning NAD+ stacks
The combinations discussed in this guide vary significantly in terms of their biological rationale, and the term „stack” can sometimes blur those distinctions.
Understanding the role of each component helps to distinguish between combinations involving distinct pathways and those that largely affect the same endpoint.
NAC and NAD+ are indirectly linked through cellular redox biology, whereas berberine acts primarily through pathways such as AMPK. Omega-3 fatty acids have their own mechanisms related to lipid signalling and inflammation.
NR is different because it is itself a precursor to NAD+. A formulation containing both NAD+ and NR therefore acts on the same underlying NAD+ system, rather than combining two clearly independent biological pathways.
Another important distinction is the difference between the absence of a known interaction and proof that a specific combination has been shown to be safe.
No dedicated human combination studies have been identified regarding NAD+ precursors together with NAC, berberine, or omega-3 fatty acids.
This does not mean that these combinations are unsafe. Rather, it means that it cannot be assumed that their combined safety and efficacy have been directly confirmed just because the individual ingredients have separate research histories.
Safety issues specific to individual ingredients remain relevant even when the compounds are part of a multi-ingredient formulation.
Berberine can affect blood glucose levels and potentially interact with medications used in diabetes. NAC has well-documented drug interactions in specific clinical situations. High doses of omega-3 fatty acids can affect blood clotting, which may be relevant when used concurrently with anticoagulant or antiplatelet drugs.
The addition of an NAD+ precursor does not remove or replace these ingredient-specific safety considerations.
The overall safety profile of the supplement stack may therefore depend on the entire formulation, the doses used, comorbid conditions and concurrently taken medications, rather than solely on the NAD+-related ingredient.
Limitations of current evidence
- No dedicated human clinical trials have been identified that specifically test NAD+ precursors in combination with NAC, berberine, or omega-3 fatty acids. The rationale for these combinations is based mainly on separate data for each ingredient.
- The mechanistic link between NAD+ precursors and NAC via NADPH and glutathione regeneration is indirect and has not been directly studied as a combination intervention [2].
- The differing molecular mass and chemical properties of NAD+ and berberine suggest that the two compounds may have significantly different absorption profiles even when they are in the same transdermal patch, which is not always adequately reflected in product marketing.
- No dedicated safety or efficacy studies have been identified for products combining direct NAD+ with NR, although no specific safety issue resulting solely from the combination of direct NAD+ with its precursor has been documented.
Disclaimer
The article is for educational purposes only and does not constitute medical advice or a recommendation for or against any specific combination of supplements.
NAD+, NR, NAC, berberine and omega-3 fatty acids should not be presented as FDA- or EMA-approved methods for preventing, treating or curing diseases, unless referring to a specific approved medicinal product and indication.
The discussed ingredients have varying evidence bases, biological mechanisms, potential interactions and safety considerations. Evidence regarding a single ingredient should not be interpreted as proof that a combination containing that ingredient has also been clinically tested or demonstrated synergistic effects. Product names mentioned in the article are for informational purposes only and do not constitute a recommendation or evidence that a specific commercial formulation has been independently clinically validated.
References
[1] Sahasrabudhe, S. A., Terluk, M. R., & Kartha, R. V. (2023). N-acetylcysteine pharmacology and applications in rare diseases—Repurposing an old antioxidant. Antioxidants, 12(7), 1316. https://doi.org/10.3390/antiox12071316
[2] Sies, H., Berndt, C., & Jones, D. P. (2017). Oxidative stress. Annual Review of Biochemistry, 86, 715–748. https://doi.org/10.1146/annurev-biochem-061516-045037
[3] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[4] Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948
[5] Shibabaw, T. (2021). Omega-3 polyunsaturated fatty acids: Anti-inflammatory and anti-hypertriglyceridaemia mechanisms in cardiovascular disease. Molecular and Cellular Biochemistry, 476(1), 993–1003. https://doi.org/10.1007/s11010-020-03965-7